Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an update.
Shandong Xinhua Pharmaceutical has updated and re-adopted the terms of reference for its Board-level Remuneration and Appraisal Committee, originally approved in 2002 and most recently revised on 31 December 2025, to align with PRC corporate law, governance codes, independent director rules, its Articles of Association and Hong Kong Listing Rules. The revised document formalises the committee’s composition, independence requirements, leadership by an independent non-executive director, member qualifications, responsibilities and confidentiality obligations, and embeds the committee within the board’s administrative structure, reinforcing remuneration oversight and governance standards for directors and senior management to better safeguard shareholder interests.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Co., Ltd. is a Hong Kong-listed pharmaceutical manufacturer based in the People’s Republic of China, operating under PRC Company Law and stock exchange regulations. The company is governed by a board of directors that includes independent non-executive directors and senior management such as the general manager, deputy general managers and the board secretary, reflecting a standard governance structure for a major listed drug producer.
Average Trading Volume: 2,147,224
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.88B
See more data about 0719 stock on TipRanks’ Stock Analysis page.